EBGCR Clinical Research Principal Investigators Provide Exceptional Care

Principal Investigators at EBGCR
Photo of Michael Ibach MD

Michael Ibach, MD

Gastroenterologist Encore Borland Groover Clinical Research
Contact Research: 9046800871

Biography

Dr. Ibach is a 2nd generation physician, whose father, Dr. John Ibach, was a local cardiothoracic surgeon in Jacksonville. Dr. Ibach attended high school at The Bolles School in Jacksonville, before receiving his bachelor’s degree in biology from Tulane University in New Orleans. He obtained his Doctor of Medicine degree in Tampa at the University of South Florida and completed his residency program for internal medicine at Albert Einstein Medical Center, Philadelphia, Pennsylvania.

Dr. Ibach returned to Louisiana to complete his gastroenterology and hepatology fellowship at Louisiana State University Medical Center, Shreveport, Louisiana. He was in private practice in Jackson, Tennessee until 2011.

Dr. Ibach returns to Jacksonville with his family, and is now based at our Jacksonville Beach location.​

Participate in Current Trials 


Eosinophilic esophagitis EoE

 


Postgraduate Education
1992 – 1995
Fellowship, Gastroenterology and Hepatology
Louisiana State University Medical Center
1989 -1992
Residency, Internal Medicine
Albert Einstein Medical Center Philadelphia, Pennsylvania
RESEARCH TRAINING:
12/14/2017 CITI Good Clinical Practice
RESEARCH EXPERIENCE:

Principal Investigator:2019-Present Adare SP-1011-003, Eosinophilic EsophagitisSub-Investigator:2020-Present Neurogastrx NG101-201, Gastroparesis2020-Present Lucid EG-CL-102, Adenocarcinoma2020-Present Lucid EG-CL-101, Barrett’s Esophagus

2020-Present Enanta EDP305-102, NASH

2020-Present Allakos AK002-014, Eosinophilic Esophagitis

2020-Present Allakos AK002-016, Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis

2020-Present Allakos AK002-019, Eosinophilic Gastrointestinal Diseases

2020-Present SERES-201, Ulcerative Colitis

2020-Present Phathom HP-301, H. Pylori

2020-Present Phathom EE-301, Erosive Esophagitis

2019-Present AbbVie M14-234, Ulcerative Colitis

2019-Present AbbVie M14-533, Ulcerative Colitis

2019-Present AbbVie M14-675, Ulcerative Colitis

2019-Present AbbVie M14-430, Crohn’s Disease

2019-Present AbbVie M14-431, Crohn’s Disease

2019-Present AbbVie M14-433, Crohn’s Disease

2019-Present Gilead GS-US-365-4237 FALCON, Ulcerative Colitis

2019-Present Braintree BLI4900-302, Colon Prep

2019 Pfizer C1061011, NAFLD

2019-Present Finch CDI-001, C-difficile

2018-2020 Shire SHP621-302, Eosinophilic Esophagitis

2018-2020 Shire SHP621-301, Eosinophilic Esophagitis

PROFESSIONAL EXPERIENCE:

3/2019-Present
Clinical Research Investigator
ENCORE Borland-Groover Clinical Research
Jacksonville, FL

4/2011-Present
Gastroenterologist
Borland Groover
Jacksonville, FL

7/1995-4/2011
Private Practice
Gastroenterology and Hepatology

Medical Specialty Clinic
Jackson, TN

Finan MA, Smith SG, Sinnott JT, Obrien W, Ibach M, Morales R. An interesting case presentation: Peripartum meningococcal meningitis. J Perinatol 1992;12:78-80.

Ibach MB. Predictors of compliance after hospitalization. J La State Med Soc 1995;147:321-324.

Grier JF, Ibach MB, Grafton WD, Gholson CF. Ischemia-induced tissue remodeling: magnetic enteral gastrostomy in a porcine model. Gastrointest Endosc1995;42:354-357.

Ibach MB, Grier JF, Goldman DE, LaFontaine S, Gholson CF. Diagnostic considerations in evaluation of patients presenting with melena and nondiagnostic esophagogastroduodenascopy. Dig Dis Sci 1995;40:1459-1462.

Gholson CF, Grier JF, Ibach MB, McMillan RW, McDonald JC. Late hepatic allograft failure associated with diffuse biliary sclerosis and ductal proliferation.Transplant proc (submitted).

Grier JF, Ibach MB, Jordan PA. Post-emetic laceration of the gastric body: A Mallory-Weiss variant. Dig Dis Sci (submitted).

Gholson CF, Grier JF, Ibach MB, Favrot D, Nall L, Sittig K, McDonald JC. Sequential endoscopic/laparoscopic management of sickle hemoglobinopathy-associated cholelithiasis and suspected choledocholithasis. South Med J 1995;88:1131-1135.

Ibach MB, Grier JF, Goldman DE, Gholson CF. Perioperative endoscopic diagnosis and management of choledocholithiasis. Am J med (submitted).

Grier JF, Ibach MB, Small VW, Spires WV, Nopajaroonsri C, Robles V. clinical pathological conference: 48 year old man with painless jaundice. J La State Med Soc(submitted).

Goldman DE, Grier JF, Coon CC, Ibach MB. Intrashincteric botulinum toxin in the treatment of achalasia: a case report and review of the literature. Am J Gastroenterol (submitted).
Abstracts

Ibach MB, Piszcz-Connelly M, Levine G. A five year follow up of patients evaluated for heme positive stools or rectal bleeding. AM J Gastroenterol 1992;97:1340.

Gholson CF, Grier JF, Ibach MB, Favrot D, Nall L, Sittig K, McDonald JC. Sequential endoscopic/laparoscopic management of sickle hemoglobinopathy-associated cholelithiasis and suspected choledocholithasis. Gastrenterology 1994;106:339.

Grier JF, Ibach MB, Gholson CF. Diagnostic considerations in evaluation of patients presenting with melena and nondiagnostic esophagogastroduodenascopy. Gastroenterology 1994;106:236.

Ibach MB, Grier JF, Goldman DE, Gholson CF. Perioperative endoscopic diagnosis and management of choledocholithiasis. Am J Gastroenterol 1994;89:1656

Goldman DE, Jordan PA, Grier JF, Ibach MB. Circumventing dysphagia. AM J Gastroenterol 1994;89-1731.

Grier JF, Ibach MB, Gholson CF. Magnetic enteral gastrostomy in a porcine model. Gastroenterol 1994;108:104.

Ibachj MB, Grier JF. A randomized trial of sedation and analgesia prior to bedside percutaneous live biopsy. Am J Gastroenterol 1995;90:1622.

Grier JF, Ibach MB, goldman DE, Jordan PE. Ethanol-induced tumor necrosis combined with serial expandable metal stents for palliation of malignant dysphagia. Am J Gastroenterol 1995;90:1559.

Exceptional care provided by EBGCR Clinical Research Principal Investigators

The Clinical Research Principal Investigators at Encore Borland Groover Clinical Research (EBGCR) strive to improve patient outcomes through cutting-edge clinical research. Our team of world-renowned specialists is committed to transforming medicine by conducting groundbreaking clinical trials. Our Clinical Research Principal Investigators are leaders in pharmacologic outcome clinical trials, particularly with new agents in Phases I-III. Our esteemed physicians can provide patients with early access to pioneering drugs by conducting clinical trials, which may only be available to the general public for a short time. With extensive clinical research expertise, our team advances medical knowledge daily and addresses serious health issues to enhance people’s lives today and tomorrow.

At EBGCR, we understand that the success of our clinical trials depends on having a team of experts dedicated to ensuring the highest research standards. Among these experts are our EBGCR Clinical Research Principal Investigators, who play a fundamental role in overseeing and guiding our studies. These experienced professionals bring a wealth of knowledge and expertise to our team, with a deep understanding of the intricacies of clinical research. Our investigators help us design and execute trials that meet the highest quality and safety standards by working closely, providing our patients with the best possible care and outcomes.

EBGCR Clinical Research Principal Investigators

904-680-0871

Contact us today

Expertise provided by Clinical Research Principal Investigators

At the heart of our mission to improve lives lies the expertise and dedication of our EBGCR Clinical Research Principal Investigators. Our entire team has a wealth of knowledge, experience, and passion for making a real difference in the world of healthcare; our investigators are committed to discovering and developing the life-saving treatments that will revolutionize how we approach patient care. Drawing on the latest advancements in medical research, our team is continually looking forward to the future of healthcare, exploring new and innovative ways to improve outcomes and unlock new possibilities for patients worldwide. At EBGCR, we believe that together, we can make a real difference in the lives of those we serve, and we are committed to doing everything we can to bring our mission of improved healthcare to energy.